AVIR
Atea Pharmaceuticals Inc

3,057
Loading...
Loading...
News
all
press releases
Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus
Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 patients did not meet the primary endpoint. The company remains focused on its hepatitis C combination therapy. read more...
Benzinga·1y ago
News Placeholder
More News
News Placeholder
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H'24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals...
Globe Newswire·2y ago
News Placeholder
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Federated Hermes Inc.
Federated Hermes Inc. decreased its stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR Free Report) by 0.8% during the 3rd quarter, according to the company in its most recent 13F filing with...
Zolmax·2y ago
News Placeholder
Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript...
SeekingAlpha·2y ago
News Placeholder
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400...
Globe Newswire·2y ago
News Placeholder
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ( Atea ), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...
Globe Newswire·2y ago
News Placeholder
Q1 2024 Earnings Forecast for Atea Pharmaceuticals, Inc. Issued By Leerink Partnrs (NASDAQ:AVIR)
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR Free Report) Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of Atea Pharmaceuticals in a research note...
Zolmax·2y ago
News Placeholder
Leerink Partnrs Research Analysts Decrease Earnings Estimates for Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR Free Report) Analysts at Leerink Partnrs reduced their FY2023 earnings per share (EPS) estimates for Atea Pharmaceuticals in a report released...
Zolmax·2y ago
News Placeholder
Atea Pharmaceuticals, Inc. Forecasted to Earn Q1 2024 Earnings of ($0.66) Per Share (NASDAQ:AVIR)
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR Free Report) Investment analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for shares of Atea Pharmaceuticals in a report...
Ticker Report·2y ago
News Placeholder
SG Americas Securities LLC Acquires New Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
SG Americas Securities LLC bought a new position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR Free Report) in the third quarter, according to its most recent filing with the Securities and...
Zolmax·2y ago

Latest AVIR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.